文献速递急性肾损伤慢性肾脏病

质子泵抑制剂与肾脏疾病:给肾内科医生的消化系统警示?

Proton Pump Inhibitors and Kidney Disease - GI Upset for the Nephrologist?
PubMed 文献 · Kidney Int Rep · 2017-01-23

本文综述了质子泵抑制剂(PPI)与肾脏疾病关联的证据,包括早期急性间质性肾炎病例报告及后续针对急性肾损伤(AKI)、慢性肾脏病(CKD)和终末期肾病(ESRD)的大型观察性研究。多数研究显示使用PPI者肾脏结局风险更高,AKI效应量约2-3倍,CKD和ESRD为1.2-1.8倍。尽管存在残余混杂可能,多项敏感性分析结果稳健,无明确指征时及时停用PPI或可减轻肾脏疾病负担。

要点

  • PPI使用与AKI风险升高约2-3倍相关,CKD和ESRD风险升高1.2-1.8倍。
  • 观察性研究虽存在混杂可能,但新使用者设计等敏感性分析结果稳健。
  • 无明确指征时应及时停用PPI,以降低人群肾脏疾病负担。

核心结论

  • 多数观察性研究显示PPI使用与肾脏不良结局风险升高相关,AKI效应量高于CKD和ESRD。
  • 鉴于PPI广泛使用,即使肾脏结局效应较小也可能造成较大公共卫生负担。

研究设计与样本

  • 本文为综述,汇总了早期急性间质性肾炎病例报告及后续大型观察性研究。
  • 纳入研究涵盖AKI、CKD和ESRD等肾脏结局。

主要发现

  • 多数研究显示使用PPI者肾脏结局风险更高,AKI效应量约2-3倍。
  • CKD和ESRD的效应量为1.2-1.8倍。
  • 许多研究采用新使用者设计、与组胺2受体拮抗剂比较及剂量反应评估等敏感性分析,结果稳健。

临床怎么用

  • 无明确指征时应及时停用PPI治疗,可能降低人群肾脏疾病负担。

局限性

  • 观察性药物流行病学研究可能受残余混杂和适应证混杂限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Widely regarded as safe and effective, proton pump inhibitors (PPIs) are among the most commonly used medications in the world today. However, a spate of observational studies suggest an association between PPI use and adverse events, including infection, bone fracture, and dementia. This review details evidence linking the use of PPI therapy to the development of kidney disease, including early case reports of acute interstitial nephritis and subsequent large observational studies of acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD). The majority of studies showed higher risk of kidney outcomes among persons prescribed PPI medications, with effect sizes that were slightly higher for AKI (∼2-3-fold) compared to CKD and ESRD (1.2-1.8-fold). Although observational pharmaco-epidemiology studies are limited by the possibility of residual confounding and confounding by indication, many of the described studies conducted rigorous sensitivity analyses aimed at minimizing these biases, including new-user design, comparison to similar agents (e.g., histamine2 receptor antagonists), and evaluation for a dose-response, with robust results. Given the widespread use of PPIs, even a small effect on kidney outcomes could result in large public health burden. Timely cessation of PPI therapy when there is no clear indication for use might reduce the population burden of kidney disease.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Toth-Manikowski S, Grams ME. Proton Pump Inhibitors and Kidney Disease - GI Upset for the Nephrologist? Kidney Int Rep. 2017. PMID: 28845467. doi:10.1016/j.ekir.2017.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。